Compare Vertex Pharmaceuticals Incorporated (VRTX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs State Street SPDR S&P Homebuilders ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B), while State Street SPDR S&P Homebuilders ETF trades at $95.99 (market cap $1.49B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 85.6× State Street SPDR S&P Homebuilders ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| VRTX | XHB | |
|---|---|---|
Market Cap | $127.55B | $1.49B |
Volume | 1,487,944 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $557.96 | $121.36 |
52-Week Low | $407.37 | $94.86 |
Typical Hold Time | 120 Days | 33 Days |
Enterprise Value | $121.68B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
XHB (SPDR S&P Homebuilders ETF) trades at $94.89, down 2.55% amid broader housing sector pressure from rising mortgage rates. Technical indicators show bearish momentum with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent news highlights institutional interest with Greenland Capital's $17.33 million investment, while new housing legislation and mixed home sales data create uncertainty. The ETF's valuation metrics remain undisclosed in current data.
The housing ETF faces headwinds from 7% mortgage rates but benefits from structural demand and policy support. Near-term performance hinges on interest rate trends and housing market data, with current technical weakness offering potential entry points for long-term housing recovery bets. Key risks include prolonged high rates and economic slowdown impacting buyer affordability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
